Implant Sciences Receives Follow-On Orders for Ten Explosive Trace Detectors to Protect Nuclear Power Plants in Japan

Five Orders in the Last Five Months Underscores Product Performance and Reliability

Marketwired

WILMINGTON, MA--(Marketwire - Jan 17, 2013) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced it received multiple contracts for a total of ten additional units of its Quantum Sniffer™ QS-H150 handheld explosives trace detectors from the Japanese nuclear power industry. There have been a total of five orders from the customer in the last five months.

"The QS-H150, with its non-radioactive source and operational excellence, continues to be a preferred detector of the Japanese nuclear power plant industry," said Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones. "The recurring follow-on orders from this industry are testimonial to its effectiveness and reliability. We look forward to continued success in important critical infrastructure protection market."

"The performance and reliability of Implant Sciences' trace detection equipment has been proven time and again by international users in markets such as critical infrastructure protection, law enforcement, and public safety," commented Glenn D. Bolduc, President and CEO of Implant Sciences. "With the recent approval of our QS-B220 system by the Transportation Security Administration, we look forward to extending the same benefits to air cargo users in the U.S."

About the Quantum Sniffer™ QS-H150 Handheld Explosives Trace Detector

The Quantum Sniffer QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer to receive product approval from the US Transportation Security Administration. Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive and narcotics trace detection systems which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact:


Implant Sciences Corporation
Company
Glenn Bolduc
CEO
978-752-1700
Email Contact

or

Investor
Laurel Moody
646-810-0608
Email Contact

Rates

View Comments